|
Feb 12
|
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
|
|
Jan 15
|
MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
|
|
Jan 9
|
Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
|
|
Jan 9
|
MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
|
|
Jan 9
|
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
|
|
Dec 28
|
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
|
|
Dec 21
|
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
|
|
Dec 5
|
MediWound (NASDAQ:MDWD) investors are sitting on a loss of 75% if they invested five years ago
|
|
Nov 27
|
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
|
|
Aug 7
|
MediWound to Report Second Quarter 2023 Financial Results
|